{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:42:05Z","timestamp":1787668925549,"version":"build-2736575974"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Shattuck Labs, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Death receptor 3 (DR3; also termed tumor necrosis factor receptor superfamily member 25 [TNFRSF25]) is the sole functional receptor for tumor necrosis factor (TNF)\u2013like cytokine 1A (TL1A) and is constitutively expressed on effector lymphoid cells in peripheral blood and in both inflamed and adjacent noninflamed tissues. Excessive DR3 signaling contributes to chronic inflammation in inflammatory bowel disease (IBD). While clinical trials of anti-TL1A antibodies have demonstrated efficacy in ulcerative colitis and Crohn disease, the stable expression pattern of DR3 suggests that receptor blockade may more effectively and durably inhibit TL1A-driven proinflammatory signaling and limit disease propagation. We describe the preclinical development of SL-325, a fully human, Fc-silent, high-affinity DR3-blocking monoclonal antibody.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Binding affinity and specificity of SL-325 were evaluated using biophysical and cell-based assays. Functional activity was assessed in peripheral blood mononuclear cells (PBMCs) from healthy donors and IBD patients, an ex vivo human intestinal inflammation model, and cynomolgus macaque toxicology studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SL-325 bound to human DR3 with picomolar affinity and high specificity while potently blocking TL1A binding without inducing DR3 agonism. SL-325 suppressed TL1A-induced proinflammatory cytokine secretion in PBMCs from healthy donors and IBD patients. In an ex vivo human intestinal model, SL-325 inhibited TL1A-driven cytokine production and preserved epithelial barrier integrity. In nonhuman primates, SL-325 was safe and well tolerated at doses up to 100\u2009mg\/kg, demonstrated dose-proportional pharmacokinetics, and led to prolonged DR3 receptor occupancy (RO) without immune activation or proliferation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These data demonstrate that SL-325 is a novel DR3-blocking antibody with the potential to provide durable inhibition of the TL1A\/DR3 axis and support the clinical development of SL-325 to treat IBD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag101","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:50:41Z","timestamp":1782388241000},"page":"1439-1451","source":"Crossref","is-referenced-by-count":1,"title":["Preclinical development of SL-325, a novel high-affinity DR3-blocking antibody for durable inhibition of the DR3\/TL1A axis in inflammatory bowel disease"],"prefix":"10.1093","volume":"32","author":[{"given":"Mahmud","family":"Hussain","sequence":"first","affiliation":[{"name":"Research & Development, Shattuck Labs Inc. , Durham, North Carolina,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6744-4077","authenticated-orcid":false,"given":"Anne Y","family":"Lai","sequence":"additional","affiliation":[{"name":"Research & Development, Shattuck Labs Inc. , Durham, North Carolina,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Franklin","sequence":"additional","affiliation":[{"name":"Research & Development, Shattuck Labs Inc. , Durham, North Carolina,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Lenz","sequence":"additional","affiliation":[{"name":"Research & Development, Shattuck Labs Inc. , Durham, North Carolina,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpita","family":"Patel","sequence":"additional","affiliation":[{"name":"Research & Development, Shattuck Labs Inc. , Durham, North Carolina,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Murr","sequence":"additional","affiliation":[{"name":"Research & Development, Shattuck Labs Inc. , Durham, North Carolina,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harunobu","family":"Kato","sequence":"additional","affiliation":[{"name":"Research & Development, Shattuck Labs Inc. , Durham, North Carolina,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9194-6348","authenticated-orcid":false,"given":"Lini","family":"Pandite","sequence":"additional","affiliation":[{"name":"Clinical Research, Shattuck Labs Inc. , Durham, North Carolina,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8070-1303","authenticated-orcid":false,"given":"Taylor H","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Research & Development, Shattuck Labs Inc. , Durham, North Carolina,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1928-4503","authenticated-orcid":false,"given":"Suresh","family":"de Silva","sequence":"additional","affiliation":[{"name":"Research & Development, Shattuck Labs Inc. , Durham, North Carolina,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"2026072823462284500_izag101-B1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3389\/fimmu.2019.00583","article-title":"TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory system of cytokines with diverse functions in gut mucosal immunity","volume":"10","author":"Valatas","year":"2019","journal-title":"Front Immunol"},{"key":"2026072823462284500_izag101-B2","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1136\/gutjnl-2024-332504","article-title":"Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD","volume":"74","author":"Bamias","year":"2025","journal-title":"Gut"},{"key":"2026072823462284500_izag101-B3","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1084\/jem.20071364","article-title":"TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease","volume":"205","author":"Pappu","year":"2008","journal-title":"J Exp Med"},{"key":"2026072823462284500_izag101-B4","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.4049\/jimmunol.1401220","article-title":"The TNF-family ligand TL1A and its receptor DR3 promote T cell-mediated allergic immunopathology by enhancing differentiation and pathogenicity of IL-9-producing T cells","volume":"194","author":"Richard","year":"2015","journal-title":"J Immunol"},{"key":"2026072823462284500_izag101-B5","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1084\/jem.20140678","article-title":"CX(3)CR1(+) mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22","volume":"211","author":"Longman","year":"2014","journal-title":"J Exp Med"},{"key":"2026072823462284500_izag101-B6","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1002\/eji.201445213","article-title":"Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL-22 production and IL-2-dependent proliferation","volume":"45","author":"Ahn","year":"2015","journal-title":"Eur J Immunol"},{"key":"2026072823462284500_izag101-B7","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.4049\/jimmunol.178.7.4033","article-title":"The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells","volume":"178","author":"Prehn","year":"2007","journal-title":"J Immunol"},{"key":"2026072823462284500_izag101-B8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/s1074-7613(02)00283-2","article-title":"TL1A is a TNF-like ligand for DR3 and TR6\/DcR3 and functions as a T cell costimulator","volume":"16","author":"Migone","year":"2002","journal-title":"Immunity"},{"key":"2026072823462284500_izag101-B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12026-013-8465-0","article-title":"Immunobiology of TNFSF15 and TNFRSF25","volume":"57","author":"Schreiber","year":"2013","journal-title":"Immunol Res"},{"key":"2026072823462284500_izag101-B10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/mi.2010.70","article-title":"Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia","volume":"4","author":"Taraban","year":"2011","journal-title":"Mucosal Immunol"},{"key":"2026072823462284500_izag101-B11","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.4049\/jimmunol.1201908","article-title":"Cloning, expression, and functional characterization of TL1A-Ig","volume":"190","author":"Khan","year":"2013","journal-title":"J Immunol"},{"key":"2026072823462284500_izag101-B12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13075-020-02198-9","article-title":"Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF","volume":"22","author":"Song","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2026072823462284500_izag101-B13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.humimm.2013.11.006","article-title":"Genetic risk and protective factors of TNFSF15 gene variants detected using single nucleotide polymorphisms in Hungarians with psoriasis and psoriatic arthritis","volume":"75","author":"K\u00e9p\u00edr\u00f3","year":"2014","journal-title":"Hum Immunol"},{"key":"2026072823462284500_izag101-B14","doi-asserted-by":"publisher","first-page":"31429","DOI":"10.1038\/srep31429","article-title":"Fine-mapping analysis revealed complex pleiotropic effect and tissue-specific regulatory mechanism of TNFSF15 in primary biliary cholangitis, Crohn\u2019s disease and leprosy","volume":"6","author":"Sun","year":"2016","journal-title":"Sci Rep"},{"key":"2026072823462284500_izag101-B15","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/rheumatology\/kes316","article-title":"Increased levels of soluble TNF-like cytokine 1A in ankylosing spondylitis","volume":"52","author":"Konsta","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"2026072823462284500_izag101-B16","author":"Llewellyn","year":"2025"},{"key":"2026072823462284500_izag101-B17","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s10067-017-3612-y","article-title":"Elevated levels of TL1A are associated with disease activity in patients with systemic sclerosis","volume":"36","author":"Xu","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2026072823462284500_izag101-B18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ibd\/izy305","article-title":"Death-Domain-Receptor 3 deletion normalizes inflammatory gene expression and prevents ileitis in experimental Crohn\u2019s disease","volume":"25","author":"Butto","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026072823462284500_izag101-B19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/fimmu.2018.00362","article-title":"Death Receptor 3 signaling controls the balance between regulatory and effector lymphocytes in SAMP1\/YitFc mice with Crohn\u2019s disease-like Ileitis","volume":"9","author":"Li","year":"2018","journal-title":"Front Immunol"},{"key":"2026072823462284500_izag101-B20","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S2468-1253(25)00129-3","article-title":"Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial","volume":"10","author":"Danese","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026072823462284500_izag101-B21","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa2314076","article-title":"Phase 2 trial of Anti-TL1A monoclonal antibody tulisokibart for Ulcerative Colitis","volume":"391","author":"Sands","year":"2024","journal-title":"N Engl J Med"},{"key":"2026072823462284500_izag101-B22","doi-asserted-by":"publisher","first-page":"i77","DOI":"10.1093\/ecco-jcc\/jjae190.0039A","article-title":"OP40 Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active Crohn\u2019s disease: results from a phase 2b, randomised, double-blind, placebo-controlled dose-ranging, basket trial (RELIEVE UCCD)","volume":"19","author":"Jairath","year":"2025","journal-title":"J Crohn Colitis"},{"key":"2026072823462284500_izag101-B23","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.4049\/jimmunol.171.9.4868","article-title":"Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease","volume":"171","author":"Bamias","year":"2003","journal-title":"J Immunol"},{"key":"2026072823462284500_izag101-B24","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1093\/hmg\/ddi379","article-title":"Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn\u2019s disease","volume":"14","author":"Yamazaki","year":"2005","journal-title":"Hum Mol Genet"},{"key":"2026072823462284500_izag101-B25","doi-asserted-by":"publisher","first-page":"e4719","DOI":"10.1371\/journal.pone.0004719","article-title":"IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein","volume":"4","author":"Michelsen","year":"2009","journal-title":"PLoS One"},{"key":"2026072823462284500_izag101-B26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/ibd\/izab193","article-title":"Antitumor necrosis factor-like Ligand 1A therapy targets tissue inflammation and fibrosis pathways and reduces gut pathobionts in ulcerative colitis","volume":"28","author":"Hassan-Zahraee","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026072823462284500_izag101-B27","doi-asserted-by":"publisher","first-page":"782788","DOI":"10.3389\/fimmu.2021.782788","article-title":"Immune complex formation is associated with loss of tolerance and an antibody response to both drug and target","volume":"12","author":"Kroenke","year":"2021","journal-title":"Front Immunol"},{"key":"2026072823462284500_izag101-B28","doi-asserted-by":"publisher","first-page":"20538","DOI":"10.1038\/s41598-022-24984-y","article-title":"A stable, engineered TL1A ligand co-stimulates T cells via specific binding to DR3","volume":"12","author":"Zwolak","year":"2022","journal-title":"Sci Rep"},{"key":"2026072823462284500_izag101-B29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/febs.13576","article-title":"Soluble TL1A is sufficient for activation of death receptor 3","volume":"283","author":"Bittner","year":"2016","journal-title":"Febs J"},{"key":"2026072823462284500_izag101-B30","doi-asserted-by":"publisher","first-page":"13451","DOI":"10.1073\/pnas.1404178111","article-title":"A TNFSF15 disease-risk polymorphism increases pattern-recognition receptor-induced signaling through caspase-8-induced IL-1","volume":"111","author":"Hedl","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026072823462284500_izag101-B31","doi-asserted-by":"publisher","first-page":"S-1257","DOI":"10.1016\/S0016-5085(26)03148-3","article-title":"TL1A Drives TH1, TH2 and TH17 pathways in human lamina propria cells in IBD","volume":"170","author":"Llewellyn","year":"2026","journal-title":"Gastroenterology"},{"key":"2026072823462284500_izag101-B32","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1172\/JCI42933","article-title":"Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation","volume":"120","author":"Schreiber","year":"2010","journal-title":"J Clin Invest"},{"key":"2026072823462284500_izag101-B33","author":"SEC","year":"2021"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/8\/1439\/68632807\/izag101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/8\/1439\/68632807\/izag101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:46:28Z","timestamp":1785296788000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/8\/1439\/8719541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,6,27]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag101","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,27]]}}}